Can-Fite BioPharma (CANF) Share-based Compensation (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Share-based Compensation came in at $133000.0 in Q4 2025, up 8.13% YoY from $123000.0 in Q4 2024, and up 8.13% on a QoQ basis from $123000.0 in Q4 2024.
Can-Fite BioPharma (CANF) Share-based Compensation (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 5 years of Share-based Compensation data on file, last reported at $133000.0 in Q4 2025.
- Quarterly Share-based Compensation rose 8.13% year-over-year to $133000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $133000.0 (up 8.13% YoY) and the FY2025 annual result came in at $340000.0, down 6.08% from the prior year.
- Share-based Compensation climbed to $133000.0 in Q4 2025, from $123000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $298000.0 in Q4 2023 to a low of $230.0 in Q4 2021.
- A 4-year average of $138557.5 and a median of $128000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 58.72% — and 2025, when it increased 8.13%.
- Tracing CANF's Share-based Compensation over 4 years: stood at $230.0 in 2021, then surged by 129465.22% to $298000.0 in 2023, then sank by 58.72% to $123000.0 in 2024, then advanced by 8.13% to $133000.0 in 2025.
- The last three Share-based Compensation figures came in at $133000.0 (Q4 2025), $123000.0 (Q4 2024), and $298000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | 133,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 133,000.00 |
| Dec 31, 2025 | 133,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Dec 31, 2021 | 230.00 |
| Dec 31, 2021 | 230.00 |
| Sep 30, 2013 | 194,000.00 |
| Sep 30, 2013 | 194,000.00 |